2Seventy Bio

Yahoo Finance • 11 months ago

Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

PRINCETON, N.J., & CAMBRIDGE, Mass., February 05, 2024--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that a notice was published in the Federal Register that the U.S. Food and Drug... Full story

Yahoo Finance • last year

Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimens Responses were significantly improved with... Full story

Yahoo Finance • last year

10 Stocks That Are About To Explode

In this piece, we will take a look at ten stocks that are about to explode. If you want to skip our background of the stock market then take a look at 5 Stocks That Are About To Explode. The stock market has been quite tumultuous recently... Full story

Yahoo Finance • 2 years ago

Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma

U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023 European Medicines Agency has validated Bristol Myers Squibb’s Type II variati... Full story

Yahoo Finance • 2 years ago

Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update

Continued progress in 2022 with corporate strategy update, end-to-end platform innovation, pipeline expansion, and acceleration of lead candidate development Partnering momentum continues with a $3 million milestone payment from 2seventy b... Full story

Yahoo Finance • 2 years ago

Medigene Receives $3 Million Milestone Payment from 2seventy bio

Milestone payment is related to the establishment of 2seventy bio’s strategic partnership with JW Therapeutics Payment provides further validation of Medigene’s end-to-end platform MARTINSRIED, Germany and MUNICH, Germany, Jan. 18, 2023... Full story

Yahoo Finance • 3 years ago

Goldman Sachs Sees These 2 ‘Strong Buy’ Stocks Skyrocketing Over 70%

Just when it looked like time to throw in the towel, the market pulled through and delivered a win. After April turned out to be the worst month since March 2020, May kicked off in a more upbeat fashion, with investors hoping the bottom mi... Full story